# Rubella (German Measles) > The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider. Source: https://medova.health/en/knowledge/diseases/rubella · Language: en ## Overview Usually mild viral infection causing a distinctive red rash. Critical risk: congenital rubella syndrome (CRS) in unvaccinated pregnant women — causes deafness, blindness, and heart defects in the fetus. ## Medical Information - ICD-10: B06 - ICD-11: 1F05 - Causative Agent: virus - Severity: Moderate - Incubation Period: 14–21 days - Mortality Rate: 0.0001% - Vaccine available: Yes ## Transmission - Droplet transmission (Primary route) - Airborne transmission ## Overview Contagious viral infection known for its distinctive red rash. ## Overview Rubella (German measles) is a mild disease in children and adults but causes devastating Congenital Rubella Syndrome when infection occurs in the first trimester of pregnancy. Prevented by the MMR vaccine. WHO declared rubella eliminated from the Americas (2015) and Europe (2023). ## Emergency Signs Seek urgent care if (mostly relevant to pregnant women and newborns): - **Pregnant woman exposed to rubella:** immediate serology required; contact obstetric services - Newborn with cataracts, heart murmur, or deafness (CRS screening) - Purpuric rash (bleeding into skin) — thrombocytopenia - Neurological symptoms: headache, confusion, seizures (encephalitis) ## Detailed Symptoms **Postnatal rubella (incubation 14–21 days):** - Low-grade fever (38–38.5°C), malaise, and upper respiratory symptoms - **Characteristic rash:** fine pink/red maculopapular rash beginning on face, spreading to trunk and limbs over 1–3 days; often fades within 3 days - **Lymphadenopathy:** suboccipital, postauricular, and posterior cervical lymph nodes enlarged and tender — may precede rash by 5–10 days - Arthralgia/arthritis (especially in adult women: ~70%) - Conjunctivitis, Forchheimer spots (petechiae on soft palate) in some cases - ~25–50% of infections are subclinical **Congenital rubella syndrome (CRS):** Classic triad: cataracts/glaucoma, sensorineural deafness, congenital heart disease (patent ductus arteriosus, pulmonary artery stenosis) ## Course of Disease **Typical disease course (postnatal):** 1. **Incubation period:** 14–21 days (average 16–18 days). 2. **Prodromal phase (1–5 days, more prominent in adults):** Low-grade fever, malaise, mild conjunctivitis, lymphadenopathy (postauricular, posterior cervical, suboccipital — characteristic). 3. **Exanthem (3 days — "3-day measles"):** Fine pinkish maculopapular rash, starting on the face, spreading to trunk and extremities within 24 hours. Fades in same order. Rash is not as confluent as measles. 4. **Resolution:** Rash resolves in 3 days. Lymphadenopathy may persist 1–2 weeks. Arthralgia in adults (especially women) may last 1–4 weeks. **Key feature:** Up to 50% of rubella infections are subclinical — serology is needed to confirm diagnosis. The rash is nonspecific and can be confused with many other viral exanthems. ## Diagnosis - **Serology:** rubella-specific IgM antibody confirms acute infection - IgG seroconversion confirms recent infection - **RT-PCR:** from nasopharyngeal swab, urine, or blood — most reliable in first week - **Prenatal/CRS:** fetal blood or amniotic fluid sampling - neonatal serology + viral culture from urine, CSF, throat - All cases must be reported - pregnant contacts require urgent risk assessment ## Treatment No specific antiviral therapy. Management: - Supportive: antipyretics, rest - NSAIDs (ibuprofen) for joint symptoms in adults - Isolation for 7 days after rash onset - **Rubella in pregnancy:** thorough counseling required regarding CRS risk: - Before 10 weeks: ~90% risk of CRS — termination may be considered - Weeks 10–12: risk decreases sharply to ~33% - 13–16 weeks: 10–20% risk; isolated sensorineural deafness is the predominant defect - After 20 weeks: rare CRS - Neonates with CRS require specialist multidisciplinary care (ophthalmology, audiology, cardiology) ## Prevention Details MMR vaccine provides 95–99% protection against rubella: - **Standard schedule:** Dose 1 at 12–15 months; Dose 2 at 4–6 years - **Pre-pregnancy screening:** all women of childbearing age should verify rubella immunity; vaccinate if seronegative (contraindicated in pregnancy — vaccinate ≥28 days before conception) - Rubella vaccination is contraindicated in pregnancy (live attenuated vaccine) - Immunoglobulin: not routinely recommended but may reduce symptoms in exposed seronegative pregnant women who decline termination ## Travel Advice - Ensure MMR vaccination before travel to any country without rubella elimination status. - **Pregnant women:** avoid travel to rubella-endemic areas; verify immunity before travel. - Outbreaks reported in parts of Africa, Asia, Middle East, Eastern Europe. - Rubella is highly contagious in non-immune populations; even brief exposure can transmit infection. ## How common is it? Before widespread vaccination, rubella was endemic globally with peak incidence in children 5–9 years. An estimated 100,000 CRS cases occur annually worldwide (mostly in Africa and Asia). WHO target: global rubella elimination and CRS prevention. Americas (2015) and European Region (2023) achieved elimination status. Outbreaks persist in Africa, Southeast Asia, and in European subpopulations with low vaccine coverage. ## Risk Factors The most significant risk factor for rubella infection is lack of immunity, whether from absent vaccination or waning immunity. Individuals who have not received rubella-containing vaccine and have no history of natural infection are susceptible. In countries without universal rubella vaccination, seroprevalence studies show susceptibility rates of 10–25% in women of childbearing age. Living in or traveling to countries where rubella is still endemic increases exposure risk. Crowded living conditions, healthcare settings, and educational institutions facilitate transmission. Healthcare workers, childcare providers, and teachers have occupational risk due to frequent contact with potentially infected individuals. The most critical risk factor is **pregnancy in a non-immune woman**. The risk of congenital rubella syndrome varies dramatically by gestational age at the time of maternal infection: approximately 85% during the first 12 weeks, 50% at 13–16 weeks, and decreasing significantly after 20 weeks. This gestational gradient underscores the importance of pre-conception immunity screening and vaccination. ## Complications Details **Postnatal complications (uncommon):** - Arthritis/arthralgia: very common in adult women (up to 70%) - Thrombocytopenic purpura: 1 in 3,000 cases - Encephalitis: 1 in 6,000 cases **Congenital Rubella Syndrome (CRS) — the critical complication:** - Cataracts and/or glaucoma (blindness risk) - Sensorineural hearing loss (most common defect) - Congenital heart disease (PDA, pulmonary stenosis) - Microcephaly, intellectual disability - Diabetes mellitus (late-onset, 20% of survivors) - Thyroid disorders - Progressive rubella panencephalitis (rare, fatal) ## Recovery & Outlook **Postnatal rubella:** Benign. Self-limiting in 3–5 days. Complications rare in children. Adults may have transient arthralgia (especially women, 70%). **Congenital Rubella Syndrome (CRS) — the critical concern:** - First-trimester maternal infection: 80–90% risk of CRS. - CRS manifestations: sensorineural deafness (60–75%), congenital heart defects (PDA, pulmonary stenosis), cataracts/glaucoma, intellectual disability, hepatosplenomegaly, thrombocytopenic purpura ("blueberry muffin" rash). - CRS carries significant lifelong morbidity and 10–20% first-year mortality. - Second-trimester infection: risk drops to 10–20%. Third trimester: CRS is rare. **Global:** Rubella elimination achieved in the Americas (2015). Vaccination programs have dramatically reduced CRS worldwide. ## Available Vaccines - [MMR Vaccine](https://medova.health/en/knowledge/vaccines/mmr-vaccine) - [Rubella](https://medova.health/en/knowledge/vaccines/rubella) ## Sources & content verification - Data sources: WHO/ICD-11, CDC, ECDC (SafeTripVax QMR-003, 2026-02-25), WHO Disease Factsheets 2024 + CDC Travelers' Health 2024 + Heymann CDD 21st ed., WHO Disease Factsheets 2024 + CDC Yellow Book 2024 + Heymann CDD 21st ed. - Generated by: AI + Human review - Review status: Awaiting medical review - Last updated: 2026-02-25 - [www.who.int](https://www.who.int/emergencies/disease-outbreak-news) - [www.who.int](https://www.who.int/news-room/fact-sheets) --- The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider. [Full terms of use](https://medova.health/en/terms)